PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
With no commercialized products, this antibody drug developer's earnings swing sharply by quarter depending on license milestone timing, with the next inflection point set for clinical results expected in 2027.
Founded in 2020, this antibody drug specialist biotech listed on KOSDAQ in March 2026 via the technology growth company special track.
In 2024 the company signed licensing deals worth a combined $1.26 billion with Navigator Medicines and Huadong Medicine, and in Q1 2026 actually received a $5 million milestone tied to clinical progress.
Capital structure normalized in 2025 after preferred shares converted to common, flipping net income from loss to profit, but Q2 2026 saw zero revenue again in the absence of a milestone.
Topline results for the global Phase 2a hidradenitis suppurativa trial of lead asset IMB-101 (NAV-240) are expected in the second half of 2027.
Sanofi is ahead in development speed within the same OX40L mechanism, making the competitive landscape another variable to watch.
IMBiologics was founded in August 2020 by CEO Ha Kyung-sik, who spent 21 years developing antibody anticancer drugs and protein biologics at CJ CheilJedang and CJ HealthCare (now HK inno.N).
The company's core technology is its optimized antibody modality platform, IM-OpDECon, which underpins its autoimmune disease and immuno-oncology antibody drug development.
Its lead pipeline consists of the bispecific antibody IMB-101 and the monoclonal antibody IMB-102, both targeting OX40L, though IMB-101 was in-licensed from HK inno.N and co-developed with Y-Biologics while IMB-102 is a self-developed candidate.
IMB-101 simultaneously suppresses TNF-alpha, a core inflammatory mediator, and OX40L, an immune cell activation signal, positioning it as a next-generation autoimmune disease therapy addressing the root cause of inflammatory conditions.
In 2024 the company signed a $940 million licensing deal with US partner Navigator Medicines and a $320 million deal with China's Huadong Medicine, together totaling roughly $1.26 billion.
IMBiologics is not a product-sales business; licensing and milestone (technology fee) revenue account for the vast majority of its earnings.
Its follow-on pipeline includes the HLA-G-targeted antibody-drug conjugate IMB-201 and a novel cancer therapeutic vaccine candidate IMB-402, both undergoing preclinical and proof-of-concept work with a goal of entering Phase 1 trials in 2028.
Competitively, Sanofi is the most advanced big pharma in the OX40L mechanism, having secured brivekimig (via the Ablynx acquisition) and amlitelimab (via the Kymab acquisition) through large-scale M&A.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | — | — | — |
| 2025Q3 | — | — | — |
| 2025Q4 | — | — | — |
| 2026Q1 | ₩7.2B | ₩2.7B | 37.8% |
| 2026Q2 | ₩0 | -₩2.7B | — |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2024 | ₩27.6B | ₩14B | -₩11.9B | 50.7% | — | −146.8% |
| 2025 | ₩11.6B | ₩300M | ₩900M | 2.6% | 1.2% | 2.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
In 2024, consolidated revenue was KRW 27.59 billion and operating profit was KRW 14.00 billion (an operating margin of 50.7%), largely reflecting recognition of large upfront licensing payments.
That same year, however, the company posted a net loss of KRW 11.88 billion, as preferred-type class shares issued before listing were classified as liabilities, with related fair-value revaluation losses pushing total equity down to negative KRW 77.20 billion.
After all of those class shares converted fully into common stock in August 2025, liabilities dropped sharply to KRW 1.81 billion and total equity completely reversed to positive KRW 73.49 billion.
Full-year 2025 revenue fell 58% year-on-year to KRW 11.62 billion and operating profit dropped 98% to KRW 297.7 million (a 2.6% operating margin), yet net income turned positive at KRW 876.9 million, flipping from loss to profit.
In Q1 2026, the company posted revenue of KRW 7.23 billion, operating profit of KRW 2.73 billion, and owner's net income of KRW 3.83 billion, reflecting a $5 million (about KRW 7.5 billion) milestone tied to the first-patient dosing completion in Navigator Medicines' global Phase 2 trial of IMB-101.
By contrast, Q2 2026 recognized no revenue at all, resulting in an operating loss of KRW 2.68 billion and a net loss of KRW 2.12 billion, illustrating the volatility of a license-based business model where results hinge heavily on whether a milestone event occurs.
Guidance presented in the listing prospectus calls for 2026 revenue of KRW 19.7 billion with an operating loss of KRW 5.5 billion, 2027 revenue of KRW 0.7 billion with an operating loss of KRW 27.4 billion, and 2028 revenue of KRW 97.7 billion with operating profit of KRW 67.3 billion — a step-function structure premised on milestone recognition tied to clinical stage progress.
In other words, the Q1 2026 profit does not imply full-year profitability, and the company itself expects a full-year operating loss.
OX40L is a target that regulates immune cell activation signals, and is viewed by some as potentially becoming a core mechanism for autoimmune disease treatment much as PD-1 became for oncology.
Sanofi acquired Ablynx in 2018 for EUR 3.9 billion (about KRW 5 trillion at the time) and Kymab in 2021 for $1.45 billion (about KRW 1.6 trillion at the time), securing brivekimig and amlitelimab respectively and deploying massive capital into the OX40L class.
In terms of development speed, Sanofi is ahead: brivekimig is already in Phase 2 trials, with indication expansion underway across Crohn's disease, type 1 diabetes, and ulcerative colitis.
By comparison, IMBiologics' NAV-240 (IMB-101) has only just begun first-patient dosing in a Phase 2a trial targeting hidradenitis suppurativa. The company argues that its next-generation, half-life-extended version NAV-242 could offer a dosing-convenience advantage versus Sanofi's biweekly-dosed brivekimig.
Within Korea's biotech industry, a business model of transferring a specific pipeline asset into a separately established company (a "NewCo") to attract outside capital is gaining traction, and IMBiologics' partner Navigator Medicines is itself a NewCo-type entity.
This model has drawn attention as a pathway for Korean biotech pipeline value to convert into outside investment or big pharma acquisition, exemplified by Pfizer's acquisition of Metsera, which held D&D Pharmatech's obesity drug pipeline.
The company's next pipeline events are the accumulation of clinical data for NAV-242 and whether IMB-102 advances into clinical trials.
IMB-102 is being developed for atopic dermatitis and showed a 31% reduction in disease markers at week two in an animal-model efficacy study; preclinical work is set to be completed this year, with Phase 1 entry planned for 2027.
IMB-101's pivotal trial, the global Phase 2a MAINSAIL study of NAV-240, is being conducted in hidradenitis suppurativa patients, with topline results expected in the second half of 2027.
Follow-on pipeline assets, the HLA-G-targeted ADC IMB-201 and the cancer vaccine IMB-402, are undergoing preclinical and proof-of-concept work with a target of entering Phase 1 trials in 2028 for each.
Eugene Investment & Securities analyst Kwon Hae-soon stated in a March 2026 report that Phase 2 clinical data disclosure in 2027 was expected to serve as a momentum driver for the stock, and that securing meaningful data could raise pipeline value through licensing to global big pharma or indication expansion.
Growth Research noted in a June 2026 report that, given Sanofi's roughly KRW 7 trillion investment into the OX40 mechanism, IMBiologics could become a key player in next-generation autoimmune disease treatment.
Shinhan Investment Corp. noted in a June 2026 report that the release of 26% of listed shares becoming tradable was a short-term supply-demand issue unrelated to fundamentals.
As a clinical-stage biotech with no commercialized products, IMBiologics' share price tends to respond more strongly to pipeline clinical data and expectations of follow-on licensing than to near-term earnings.
Although net income turned from loss to profit in 2025, the scale was modest, so current trading levels are largely interpreted as reflecting market expectations for future milestone inflows rather than recently confirmed profit.
Measured against the sharply expanded equity base since 2025, the stock trades at a premium to net asset value, a characteristic commonly seen among drug-development biotechs. With no dividend payment history, the investment case centers on pipeline value and clinical timelines rather than dividend appeal.
Because results swing sharply by quarter depending on when milestones occur, it is difficult to draw firm valuation conclusions from any single quarter's profit or loss.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
Two large licensing deals in 2024 secured combined agreements worth $1.26 billion, and Q1 2026 saw an actual inflow of a $5 million milestone tied to clinical progress, demonstrating the deals' executability. This is notable because it went beyond a mere deal announcement and translated into actual cash inflow.
Sanofi validated the commercial viability of the OX40L mechanism itself through large-scale M&A that secured brivekimig and amlitelimab. Growth Research cited Sanofi's roughly KRW 7 trillion investment as grounds for its view that IMBiologics could become a key player in the field.
Following the class-share conversion in August 2025, liabilities fell sharply and equity normalized, with existing cash reserves further bolstered by IPO proceeds and milestone receipts, according to market commentary.
Given average annual R&D spending in the KRW 6 billion range over the past two years, some observers see limited near-term funding pressure.
In quarters without a milestone event, such as Q2 2026, no revenue at all is recognized, structurally flipping results into an operating loss. This reflects a fundamental limitation of a license-based biotech with no commercialized products, reducing predictability.
Under the profit-and-loss estimates presented in the prospectus, the 2027 operating loss is projected to widen to KRW 27.4 billion from the 2026 level, implying continued near-term profitability deterioration, with a return to profit pushed out to 2028 or later.
While Sanofi's competing OX40L-class program brivekimig is already in Phase 2 across multiple indications, IMBiologics' NAV-240 is only at the early stage of a Phase 2a trial in hidradenitis suppurativa, reflecting a gap in development speed.
Because milestone revenue recognition depends on clinical progress and contractual fulfillment timing, any trial delay or change in contract terms could push back the timing of results assumed in guidance, a variable widely flagged across the industry.
Since both IMB-101 and IMB-102 are based on the OX40L target, a clinical failure or regulatory issue affecting a competing drug in the same mechanism class could disproportionately impact the value of the company's entire pipeline, given limited target diversification.
With a significant portion of listed shares having become tradable following lock-up expiration, short-term supply-demand volatility may exist, compounded by the low revenue visibility typical of clinical-stage biotechs, which can amplify share price swings.
The Q3 2026 regular report is due - worth checking whether earnings volatility recurs depending on whether a milestone event occurred.
Watch for confirmation of IMB-102's Phase 1 IND filing for atopic dermatitis and completion of preclinical work.
Whether IMB-102 actually enters Phase 1 trials will serve as a gauge of the company's in-house pipeline capabilities.
Topline results from the global Phase 2a MAINSAIL trial of NAV-240 (IMB-101) - confirmation of efficacy in hidradenitis suppurativa is the key variable for future follow-on licensing and company valuation.
IMBiologics is an antibody drug developer whose earnings are built entirely on licensing upfronts and milestone revenue rather than commercialized product sales.
A large licensing upfront recognized in 2024 temporarily lifted operating margins, but revenue and operating profit fell sharply in 2025, even as capital structure normalized following the class-share conversion, flipping net income to profit.
Results continued to swing sharply by quarter into 2026, with a milestone-driven profit in Q1 followed by a return to loss in Q2 when no revenue was recognized at all.
Company guidance assumes continued losses through 2026-2027 followed by a swing to profit in 2028 on the back of clinical progress, meaning realization depends on adherence to future clinical timelines.
The key catalysts to watch are the Phase 2a hidradenitis suppurativa results for IMB-101 (NAV-240), expected in the second half of 2027, and whether IMB-102 advances into clinical trials, alongside the progress of competing OX40L-class programs such as Sanofi's.
Investors should factor in the business model's characteristic of quarterly results shifting dramatically depending on milestone timing.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.